Hubei Guangji Pharmaceutical Co., Ltd. Stock

Equities

000952

CNE0000010R5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-19 pm EDT 5-day change 1st Jan Change
6.33 CNY +1.77% Intraday chart for Hubei Guangji Pharmaceutical Co., Ltd. -2.62% -20.78%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 798M 110M Sales 2023 738M 102M Capitalization 2.83B 391M
Net income 2022 50M 6.92M Net income 2023 -140M -19.36M EV / Sales 2022 3.69 x
Net Debt 2022 232M 32.1M Net Debt 2023 500M 69.22M EV / Sales 2023 4.51 x
P/E ratio 2022
53.6 x
P/E ratio 2023
-20.2 x
Employees 1,256
Yield 2022 *
-
Yield 2023
-
Free-Float 64.63%
More Fundamentals * Assessed data
Dynamic Chart
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangji Pharmaceutical Gets Nod to Produce Entecavir MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangji Pharma to Establish Joint Innovation Laboratory With Jiangnan University MT
Guangji Pharma to Borrow 281 Million Yuan From Bank to Support Acquisition Deals MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Guangji Pharmaceutical Announces Profit Distribution Proposal for 2022 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangji Pharma Registers Diabetes-Related Infection Drug MT
Hubei Guangji Pharma to Invest 468 Million Yuan in Parkson Biotechnology Amid Bankruptcy Reorganization MT
Hubei Guangji Pharma Signs 6MW Solar Power Project MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangji Pharmaceutical Unit to Resume Production After Three-Month Stoppage MT
More news
1 day-2.05%
1 week-4.31%
Current month+5.42%
1 month+22.20%
3 months+27.72%
6 months-23.59%
Current year-22.15%
More quotes
1 week
6.10
Extreme 6.1
6.42
1 month
4.97
Extreme 4.97
7.85
Current year
4.11
Extreme 4.11
8.29
1 year
4.11
Extreme 4.11
8.80
3 years
4.11
Extreme 4.11
9.09
5 years
4.11
Extreme 4.11
10.08
10 years
4.11
Extreme 4.11
23.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 21-04-21
Director of Finance/CFO 54 16-09-13
Chief Tech/Sci/R&D Officer 47 -
Members of the board TitleAgeSince
Director/Board Member 47 21-04-21
Director/Board Member 55 15-01-05
Corporate Officer/Principal 60 -
More insiders
Date Price Change Volume
24-05-19 6.33 +1.77% 11 059 890
24-05-17 6.22 -2.05% 11,065,470
24-05-16 6.35 +2.92% 17,559,390
24-05-15 6.17 -1.28% 10,605,990
24-05-14 6.25 -3.40% 19,782,560

End-of-day quote Shenzhen S.E., May 16, 2024

More quotes
Hubei Guangji Pharmaceutical Co., Ltd. is the Chinese leader of pharmaceutical ingredients production. The group's activity is organized around four product families: - vitamins: riboflavin and beta carotene; - food supplements; - fine chemistry products; - medicinal preparations.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000952 Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW